| Study characteristics |
| Methods |
To investigate the association between conflicts of interest among guideline authors and the guidelines' recommendations in two clinical guidelines on treatment of psoriasis by gabapentin versus efalizumab |
| Data |
Two clinical guidelines |
| Comparisons |
One clinical guideline with financial conflicts of interest (defined as at least one author with financial ties to drug companies) and one clinical guideline without financial conflicts of interest |
| Outcomes |
Recommendations (favourable recommendations defined as efalizumab being judged more favourable) |
| Funding source |
Funding source not described |
| Declaration of conflicts of interest |
The authors disclosed no conflicts of interest related to any for‐profit organisation |
| Notes |
|
| Risk of bias |
| Item |
Authors' judgement |
Support for judgement |
| Adequate document inclusion process |
No |
No systematic search for guidelines |
| Adequate coding of conflicts of interest |
No |
Only one author coded each guideline |
| Adequate coding of recommendations |
No |
No systematic procedure for coding the recommendations of each guideline |
| Adequate dealing with confounding |
Yes |
Compared two guidelines of the same drug used for the same disease and published in the same year |
